Perioperative Dexamethasone for Brain Tumor Resection

Introduction to Perioperative Dexamethasone Use

The American College of Oncology recommends initiating dexamethasone only in patients with symptomatic brain tumors, starting at 4-8 mg/day for mild symptoms or 16 mg/day for moderate-to-severe symptoms, and tapering as rapidly as clinically tolerated postoperatively, as prophylactic perioperative steroid use is increasingly discouraged due to evidence linking steroids to inferior survival and immunotherapy interference 1, 2.

The National Comprehensive Cancer Network suggests starting dexamethasone only in patients with neurological deficits requiring symptomatic relief, as clinically asymptomatic patients seldom require steroid treatment even with radiographic edema present on imaging 1, 3.
The American College of Oncology advises that prophylactic perioperative steroid use is increasingly discouraged because strong evidence links steroid use to inferior survival in glioblastoma patients, and steroids may be detrimental in patients receiving immunotherapy for primary and metastatic brain tumors 1, 3.

For patients with mild symptoms, such as headache or minimal focal deficits, the American College of Oncology recommends initiating dexamethasone 4-8 mg/day as a single daily oral or intravenous dose, which provides equivalent symptomatic relief compared to higher doses in patients without impending herniation 1, 2.
For patients with moderate-to-severe symptoms, such as significant mass effect or elevated intracranial pressure, the American College of Oncology suggests initiating dexamethasone 16 mg/day or higher 1, 2.

The American College of Oncology recommends tapering dexamethasone as rapidly as clinically tolerated, with typical tapering occurring over 2-4 weeks, but patients with long-term steroid use may require longer tapering periods 1, 2, 3.

The American Thoracic Society states that dexamethasone is the drug of choice due to its potent glucocorticoid activity with minimal mineralocorticoid effects, avoiding undesirable blood electrolyte alterations and fluid retention 1, 4, 2, 3.

The National Comprehensive Cancer Network recommends providing trimethoprim-sulfamethoxazole prophylaxis for patients requiring steroid treatment >4 weeks, those undergoing concurrent radiation or chemotherapy, or those with lymphocyte count <1000/ml 1, 3, 5.
The American College of Chest Physicians advises monitoring for steroid-related complications, including hyperglycemia, infections, gastrointestinal bleeding, psychiatric disturbances, metabolic derangements, arterial hypertension, osteoporosis, and steroid-induced myopathy 6, 4, 1, 3.

The American College of Oncology warns that long-term steroid use (>3 weeks) is associated with significant toxicity, including suppressed immunity and metabolic disturbances 6, 1, 3.
The American College of Oncology notes that steroids may interact with antiepileptic drugs and immunotherapeutics, requiring critical evaluation before administration 1, 3.

Prolonged dexamethasone use suppresses the hypothalamic-pituitary-adrenal (HPA) axis, and abrupt discontinuation can precipitate life-threatening adrenal crisis, according to the Society for Neuro-Oncology 7, 8
The Society for Neuro-Oncology explicitly states that corticosteroids "should be tapered rather than abruptly discontinued given...the potential for adrenal insufficiency" 7, 8

Vasogenic edema improves gradually with oncologic therapy (surgery, radiation, or systemic treatment), requiring parallel steroid reduction to match the pace of edema resolution 7, 8
Abrupt cessation can lead to rebound edema and neurological deterioration, as the underlying pathophysiology has not yet fully resolved 7
The Congress of Neurological Surgeons emphasizes that tapering should occur "as rapidly as possible, but no faster than clinically tolerated, on the basis of an individualized treatment regimen" 9, 10

The goal is to minimize total steroid exposure while avoiding precipitous withdrawal, as stated by the Society for Neuro-Oncology and the Congress of Neurological Surgeons 7, 8, 9

While tapering should be as rapid as clinically tolerated, prolonged steroid exposure carries significant morbidity including infections, metabolic derangements, myopathy, psychiatric disturbances, and potentially inferior survival in glioblastoma patients 7, 8, 9

Vasogenic edema from intracranial lesions results from disrupted blood-brain barrier integrity, and dexamethasone reduces this through glucocorticoid receptor-mediated mechanisms that stabilize endothelial tight junctions, allowing for gradual reduction of steroids as the underlying lesion responds to treatment 7, 8